Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Endometrial Cancer

  • End date
    Apr 24, 2027
  • participants needed
  • sponsor
    Peking University People's Hospital
Updated on 24 January 2021
platelet count
neutrophil count
endometrial carcinoma
endometrial adenocarcinoma


Endometrial cancer is the most common gynecological malignancy affecting women's health. About 15% of the patients will have local late disease (stage III) with high risk of recurrence and tumor related mortality. There is a consensus that adjuvant radiochemotherapy is needed for stage endometrial cancer, but the best modality of radiochemotherapy is still uncertain. The retrospective data of our center showed that the sequential radiochemotherapy of "chemotherapy-radiotherapy-chemotherapy" in the "sanwich" mode could improve the survival outcome in patients with advanced endometrial cancer. A multicenter, prospective, randomized controlled study to compare the "sanwich" mode of radiochemotherapy and the "concurrent chemoradiotherapy followed by chemotherapy" mode will be carried out to determine the better modality of radiochemotherapy in stage III endometrial adenocarcinoma.

Condition Endometrial Carcinoma, Uterine Cancer, Endometrial Cancer
Treatment sequential radiochemotherapy in a "sanwich" mode
Clinical Study IdentifierNCT04453904
SponsorPeking University People's Hospital
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

patients of primary treatment
All patients must have undertaken comprehensive staging operationSurgery must have included a hysterectomy and bilateral salpingooophorectomy and surgical staging)
Patients with endometrial adenocarcinoma confirmed by postoperative patholog
All patients with Surgical Stage III endometrial carcinoma according to FIGO 2009 staging criteria
Entry into the study is limited to no more than 8 weeks from the date of surgery
Patients with adequate organ function, reflected by the following parameters
WBC Normal value of the institution
Absolute neutrophil count (ANC) Normal value of the institution
Platelet count 100,000/mcl
SGOT, SGPT, and alkaline phosphatase 1.25 X upper limit of normal (ULN)
Bilirubin 1.5 X ULN
Creatinine institutional ULN
Patients with a Karnofsky score60
The patients should voluntarily join the study, sign an approved informed consent with good compliance and cooperation with the follow-up

Exclusion Criteria

Patients who have received prior adjuvant therapy (radiotherapy or chemotherapy or endocrine therapy)
Patients with residual tumor after surgery
Patients with other invasive malignancies
Patients with contraindications of radiotherapy and chemotherapy (with a history of myocardial infarction within 3 month, unstable angina pectoris or history of uncontrolled arrhythmia s from the date of registration) and who cannot receive postoperative adjuvant radiotherapy and chemotherapy
Patients with an estimated survival of less than 6 months
Those who are unable or unwilling to comply with the research requirements
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note